Angiostatin receptor annexin II in vascular tumors including angiosarcoma

Human Pathology

Volumn 38, Issue 3, 2007, Pages 508-513

  Syed, Sajjad P ^a   Martin, Anne Marie ^b   Haupt, Helen M ^c   Arenas Elliot, Carmen P ^c   Brooks, John J ^c  

^a KAISER PERMANENTE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c PENNSYLVANIA HOSPITAL   (United States)

Author keywords

Angiogenesis; Angiostatin receptor; Annexin II receptor; Vascular tumors

Indexed keywords

ANGIOSTATIN; ANGIOSTATIN RECEPTOR; ANTIBODY; CALCIUM BINDING PROTEIN; CELL SURFACE RECEPTOR; LIPOCORTIN 2; PHOSPHOLIPID BINDING PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ANGIOLIPOMA; ANGIOSARCOMA; ARTICLE; BENIGN TUMOR; CAPILLARY HEMANGIOMA; CAVERNOUS HEMANGIOMA; CELL MEMBRANE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; FEMALE; HEMANGIOENDOTHELIOMA; HUMAN; HUMAN TISSUE; MALE; MALIGNANT NEOPLASTIC DISEASE; PERICYTE; PROTEIN EXPRESSION; SOFT TISSUE TUMOR; STAINING; VASCULAR ENDOTHELIUM; VASCULAR TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANNEXIN A2; FEMALE; HEMANGIOMA; HEMANGIOSARCOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, VASCULAR TISSUE;

EID: 33846886732     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.09.011     Document Type: Article

References (18)

1. Chasserot-Golaz S., Vitale N., Sagot I., et al. Annexin II in exocytosis: catecholamine secretion requires the translocation of p36 to the subplasmalemmal region in chromaffin cells. J Cell Biol 133 (1996) 1217-1236
2. Puisieux A., Ji J., and Ozturk M. Annexin II up-regulates cellular levels of p11 protein by a post-translational mechanisms. Biochem J 313 (1996) 51-55
3. Hubaishy I., Jones P.G., Bjorge J., et al. Modulation of annexin II tetramer by tyrosine phosphorylation. Biochemistry 34 (1995) 14527-14534
4. Benevolensky D., Belikova Y., Mohammadzadeh R., et al. Expression and localization of the annexins II, V, and VI in myocardium from patients with end-stage heart failure. Lab Invest 80 (2000) 123-133
5. Ohkawara M., Kuroiwa T., and Numano F. Immunohistochemical studies on annexin I and II in Takayasu arteritis. Ann N Y Acad Sci 947 (2001) 390-393
6. Moser T.L., Stack M.S., Asplin I., et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A 96 (1999) 2811-2816
7. Tuzynski G.P., Sharma M.R., Rothman V.L., and Sharma M.C. Angiostatin binds to tyrosinase substrate annexin II through the lysine-binding domain in endothelial cells. Microvasc Res 64 (2002) 462-488
8. Dreier R., Schmid K.W., Gerke V., and Reihemann K. Differential expression of annexin I, II, and IV in human tissue: an immunohistochemical study. Histochem Cell Biol 110 (1998) 137-148
9. Sun M., Liu Y., and Gibb W. Distribution of annexin I and II in term human fetal membranes, decidua and placenta. Placenta 17 (1996) 181-184
10. Eberhard D.A., Brown M.D., and Vandenberg S.R. Alterations of annexin expression in pathological neuronal and glial reactions. Immunohistochemical localization of annexins I, II (p36 and p11 subunits), IV, and VI in the human hippocampus. Am J Pathol 145 (1994) 640-649
11. Kim T.T., Chen C.T., and Huang C.C. Expression of annexin II in human middle ear cholesteotoma. Otolaryngol Head Neck-Surg 118 (1998) 324-328
12. Roseman B.J., Bollen A., Hsu J., Lamborn K., and Israel M.A. Annexin II marks astrocytic brain tumors of high histologic grade. Oncol Res 6 (1994) 561-567
13. Schwartz-Albiez R., Koretz K., Moller P., and Wirl G. Differential expression of annexins I and II in normal and malignant human mammary epithelial cells. Differentiation 52 (1993) 229-237
14. Barwise J.L., and Walker J.H. Annexins II, IV, V and VI relocate in response to rises in intracellular calcium in human foreskin fibroblasts. J Cell Sci 109 (1996) 247-255
15. O'Reilly M.S., Holmgren L., Chen C., and Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2 (1996) 689-692
16. Kaushal V., Mukunyadzi P., Dennis R.A., et al. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clin Cancer Res 11 (2005) 584-593
17. Davis D.W., Takamori R., Raut C.P., et al. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antogonists SU5416 or SU6668. Clin Cancer Res 11 (2005) 678-689
18. Sieman D.W., Bibby M.C., Dark G.C., et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11 (2005) 416-420